2.08
price up icon13.04%   0.24
after-market Handel nachbörslich: 2.00 -0.08 -3.85%
loading

Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten

pulisher
Nov 21, 2024

Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN

Nov 21, 2024
pulisher
Nov 21, 2024

QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com UK

Nov 21, 2024
pulisher
Nov 16, 2024

Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat

Nov 16, 2024
pulisher
Nov 14, 2024

QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire

Nov 13, 2024
pulisher
Nov 13, 2024

Quince Therapeutics Advances Phase 3 Trial with $47.8M Cash Runway Through 2026 | QNCX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Quince Therapeutics' EryDex Shows Promise in Phase 3 Ataxia Trial, Key Data Revealed | QNCX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Quince Therapeutics reports positive safety data for EryDex - Investing.com India

Nov 12, 2024
pulisher
Nov 11, 2024

Quince Therapeutics reports positive safety data for EryDex By Investing.com - Investing.com UK

Nov 11, 2024
pulisher
Nov 11, 2024

Quince Therapeutics' EryDex Shows Promising Safety Data in Phase 3 A-T Trial | QNCX Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 08, 2024

Quince Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - XM

Nov 08, 2024
pulisher
Nov 07, 2024

Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group - MarketBeat

Nov 07, 2024
pulisher
Oct 31, 2024

Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

QNCX stock touches 52-week high at $1.44 amid market optimism - Investing.com UK

Oct 30, 2024
pulisher
Oct 30, 2024

Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Rodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN

Oct 29, 2024
pulisher
Oct 24, 2024

US Penny Stocks To Watch In October 2024 - Yahoo Finance

Oct 24, 2024
pulisher
Oct 23, 2024

Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada

Oct 23, 2024
pulisher
Oct 14, 2024

Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire

Oct 14, 2024
pulisher
Sep 25, 2024

Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World

Sep 25, 2024
pulisher
Sep 20, 2024

Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals

Sep 20, 2024
pulisher
Sep 12, 2024

Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR

Sep 12, 2024
pulisher
Sep 04, 2024

Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Quince Therapeutics CEO acquires $107k in company stock - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Sep 03, 2024
pulisher
Sep 02, 2024

The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News

Sep 02, 2024
pulisher
Aug 24, 2024

Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World

Aug 24, 2024
pulisher
Aug 23, 2024

Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World

Aug 23, 2024
pulisher
Aug 21, 2024

Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com

Aug 21, 2024
pulisher
Aug 21, 2024

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha

Aug 19, 2024
pulisher
Aug 17, 2024

Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena

Aug 16, 2024
pulisher
Aug 15, 2024

Phase III data on Quince Therapeutics’ EryDex - The Pharma Letter

Aug 15, 2024
pulisher
Aug 15, 2024

Quince Therapeutics reports progress in A-T treatment study - Investing.com

Aug 15, 2024
pulisher
Aug 15, 2024

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - StockTitan

Aug 15, 2024
pulisher
Aug 14, 2024

Quince Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle

Aug 14, 2024
pulisher
Aug 14, 2024

Market Resilience: Quince Therapeutics Inc (QNCX) Finishes Weak at 0.58, Down -16.54 - The Dwinnex

Aug 14, 2024
pulisher
Aug 13, 2024

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan

Aug 13, 2024
pulisher
Jul 26, 2024

Quince Therapeutics (NASDAQ:QNCX) Trading Up 2.6% - Defense World

Jul 26, 2024
pulisher
Jul 07, 2024

Reviewing Genenta Science (NASDAQ:GNTA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World

Jul 07, 2024
pulisher
Jun 26, 2024

Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial - Clinical Trials Arena

Jun 26, 2024
pulisher
Jun 25, 2024

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia ... - Business Wire

Jun 25, 2024
pulisher
Jun 25, 2024

Quince Therapeutics (NASDAQ:QNCX) versus Kymera Therapeutics (NASDAQ:KYMR) Critical Review - Defense World

Jun 25, 2024
pulisher
Jun 25, 2024

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Business Wire

Jun 25, 2024
pulisher
Jun 22, 2024

Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Jun 22, 2024
pulisher
Jun 21, 2024

Quince Therapeutics faces Nasdaq delisting over share price - Investing.com

Jun 21, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):